EarningsSTERIS outpaced consensus with quarterly sales of $1,396 million, showcasing double-digit organic growth and surpassing expectations.
Financial PerformanceManagement raised full-year 2024 top-line growth forecasts, reflecting confidence in the company's ongoing performance and market position.
Strategic MovesThe sale of the non-core dental business to Peak Rock Capital is a positive move, allowing Steris to focus on its core Hospital, Life Sciences, and Applied Sterilization franchises.